These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17189389)

  • 1. Effective strategies for tumors affecting chemopreventive metabolism.
    Buters JT
    Clin Cancer Res; 2006 Dec; 12(24):7203-4. PubMed ID: 17189389
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic significance of ectophosphatase inhibitors in reversal of multi-drug resistance.
    Kannan S
    Med Hypotheses; 2006; 66(5):1041-2. PubMed ID: 16446053
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.
    Rochat B
    Curr Cancer Drug Targets; 2009 Aug; 9(5):652-74. PubMed ID: 19686091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein in adult solid tumors. Expression and prognostic significance.
    Leighton JC; Goldstein LJ
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):251-73. PubMed ID: 7642464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
    Li XH; Li C; Xiao ZQ
    J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug retention, efflux, and resistance in tumor cells.
    Krishan A; Fitz CM; Andritsch I
    Cytometry; 1997 Dec; 29(4):279-85. PubMed ID: 9415409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice].
    Grishanov AIu; Kaledin VI; Zueva TV; Nekhoroshkova EK; Nikolin VP; Liakhovich VV
    Biomed Khim; 2003; 49(1):27-34. PubMed ID: 14569871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
    Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
    Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the molecular basis for tumour hypoxia.
    Carroll VA; Ashcroft M
    Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of cancer drug resistance.
    Gottesman MM
    Annu Rev Med; 2002; 53():615-27. PubMed ID: 11818492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in clinical oncology and hematology. Introduction.
    Fisher GA; Sikic BI
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):xi-xii. PubMed ID: 7642462
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug metabolism by tumours: its nature, relevance and therapeutic implications.
    Michael M; Doherty MM
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):783-803. PubMed ID: 18028025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
    Rochat B
    Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of multidrug resistance in cancer.
    Gillet JP; Gottesman MM
    Methods Mol Biol; 2010; 596():47-76. PubMed ID: 19949920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
    Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The possible use of hypericin to overcome drug resistance in cancer treatment.
    Ni G; Chi M; Chen J
    Chem Biol Interact; 2011 Apr; 190(2-3):188-9; author reply 190. PubMed ID: 21168397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.